AbbVie: agreement to acquire ImmunoGen
This acquisition accelerates AbbVie's commercial and clinical presence in solid tumors. In addition, ImmunoGen's portfolio of promising next-generation solutions complements its existing ADC platform and programs.
AbbVie will acquire all outstanding shares of ImmunoGen at a price of $31.26 per share, valuing the group at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to customary closing conditions.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction